Does TRT really require routine blood donation? Not always

What did @rachaelnicholson22 actually say?

The creator's core argument is that blood donation during TRT is not inevitable and should not be treated as routine. She warns that frequent phlebotomy can "deplete all your iron stores" and leave patients anemic, recreating the fatigue and low motivation symptoms they started therapy to fix. She also argues that elevated red blood cell counts should trigger an investigation into underlying causes, not just a standing order to donate blood. Her proposed solution is careful dose management, often "rarely just once a week," combined with close lab monitoring including sex hormone binding globulin (SHBG) values.

That is a more nuanced position than most TRT content online, which tends to treat therapeutic phlebotomy as a standard, unremarkable part of the protocol. She deserves credit for questioning that default.

Does the science back this up?

Mostly, yes. The concern about TRT-induced erythrocytosis, meaning elevated hematocrit and hemoglobin, is well established. Testosterone stimulates erythropoiesis primarily by suppressing hepcidin and increasing erythropoietin production. The clinical worry is not cosmetic. A hematocrit above 54 percent is associated with increased blood viscosity and, in some studies, elevated cardiovascular risk.

The iron-depletion warning is also real. Bachman et al. (2014, Journal of Clinical Endocrinology and Metabolism) demonstrated that repeated phlebotomy in TRT patients does produce iron-deficient erythropoiesis without actually resolving the underlying stimulus. Patients ended up with high red cell counts and depleted iron stores simultaneously, exactly the paradox she describes. That is not a hypothetical edge case. It happens with enough regularity that several endocrinology societies have started questioning whether phlebotomy is the right first-line response to elevated hematocrit on TRT.

Her point about underlying conditions is also supported. Polycythemia vera, sleep apnea-driven erythrocytosis, and COPD can all elevate red blood cell counts independently of testosterone. Dismissing those possibilities is a real clinical failure.

What did they get wrong (or right)?

The biggest problem is a claim she makes confidently but without qualification: "you do not have to donate blood if you are on testosterone replacement therapy." That is too absolute. For some patients, particularly those on injectable testosterone who respond with significant hematocrit elevation regardless of dose optimization, therapeutic phlebotomy remains clinically appropriate. The Endocrine Society's clinical practice guidelines acknowledge phlebotomy as a legitimate management tool when hematocrit exceeds 54 percent and dose reduction has not resolved it.

Her framing of SHBG as a primary dosing variable is interesting but she does not explain why, which leaves viewers with a name to drop but no actual understanding. SHBG affects free testosterone availability, so it is relevant, but presenting it as a lab-driven dosing target without context risks making it sound more determinative than the evidence supports.

What she gets unambiguously right: the "donate blood and move on" approach is genuinely overused in low-oversight TRT clinics, and the downstream consequences of iron-deficient erythropoiesis are real and underappreciated by patients.

What should you actually know?

If you are on TRT and your provider is ordering routine phlebotomy without ever discussing dose adjustment, route of administration, or evaluation for secondary causes, that is a legitimate red flag. Injectable testosterone, especially at higher doses or more frequent intervals, produces more erythrocytosis than gels or patches. Switching delivery methods or reducing dose are first-line options before defaulting to phlebotomy.

If your hematocrit is elevated, the workup should include sleep apnea screening, hydration status, smoking history, and a consideration of polycythemia vera if counts are significantly above normal. Tefferi and Barbui (2019, American Journal of Hematology) provide a useful framework for distinguishing primary from secondary erythrocytosis.

Iron studies matter. If you are donating blood every few months on TRT, ask your provider to check ferritin and iron saturation, not just a CBC. Running iron-deficient while technically polycythemic is not a theoretical concern. It is a documented outcome of unmonitored phlebotomy protocols.

Finally, no single lab value, including SHBG, should be driving dosing decisions in isolation. TRT management requires looking at total testosterone, free testosterone, hematocrit, lipids, and symptom response together. Anyone telling you otherwise is oversimplifying.